Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection

References

• MühlbergerNSRLettmeierBSroczynskiGZeuzemSSiebertUHCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence m, and mortalityBMC Public Health2009122934 PMC2656539. RPPPCP19161623
   PubMed Web of Science ®Google Scholar
• WHOHEPATITIS C2002 http://www.who.int/csr/disease/hepatitis/Hepc.pdf
   Google Scholar
• Health Protection Agency (Hepatitis C in UK) http://wwwhpaorguk/hepC2009
   Google Scholar
• ScotlandHP Hepatitis C in Scotland http://wwwdocumentshpsscotnhsuk/ewr/pdf2009/0918pdf
   Google Scholar
• PatelHHEWhen to treat and the benefits of treating hepatitis C in patients with haemophiliaHaemophilia2009151203218976253
   PubMed Web of Science ®Google Scholar
• AlterHJPRShihJWMelpolderJCHoughtonMChooQLKuoGDetection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitisN Engl J Med1989113032122149415002509915
   PubMed Web of Science ®Google Scholar
• PoynardTBedossaPOpolonPNatural history of liver fibrosis progression in patients with chronic hepatitis CThe Lancet19973499055825832
   PubMed Web of Science ®Google Scholar
• MattssonLSAWeilandOOutcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markersLiver1993132742787505044
   PubMedGoogle Scholar
• TremoladaFCCAlbertiADragoCTaggerARiberoMLRealdiGLong-term follow-up of non-A, non-B (type C) post-transfusion hepatitisJ Hepatol1992111632732811487603
   PubMed Web of Science ®Google Scholar
• Di BisceglieAMGZIshakKGHoofnagleJHMelpolderJJAlterHJLong-term clinical and histopathological follow-up of chronic post-transfusion hepatitisHepatology1991121469699741959884
   PubMed Web of Science ®Google Scholar
• KoretzRLAHColemanEGitnickGNon-A, non-B post-transfusion hepatitis – looking back in the second decadeAnn Intern Med19931191101158512159
   PubMed Web of Science ®Google Scholar
• TongMJEl-FarraNSReikesARCoRLClinical Outcomes after Transfusion-Associated Hepatitis CN Engl J Med1995June 133222146314667739682
   PubMed Web of Science ®Google Scholar
• YanoMKumadaHKageMIkedaKShimamatsuKInoueOThe long-term pathological evolution of chronic hepatitis CHepatology1996236133413408675148
   PubMed Web of Science ®Google Scholar
• KiyosawaKSTTanakaEGiboYInterrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virusHepatology19901246716752170265
   PubMed Web of Science ®Google Scholar
• NiederauCLSHeintgesTErhardtABuschkampMHürterDNawrockiMKruskaL HFPetryWHäussingerDPrognosis of chronic hepatitis c: Results of a large, prospective cohort studyHepatology1998286168716959828236
   PubMed Web of Science ®Google Scholar
• VogtMLangTFrosnerGKlinglerCSendlAFZellerAPrevalence and Clinical Outcome of Hepatitis C Infection in Children Who Underwent Cardiac Surgery before the Implementation of Blood-Donor ScreeningN Engl J Med19999163411286687010498458
   PubMed Web of Science ®Google Scholar
• SeeffLBHFAlterHJWrightECLong-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative studyHepatology200133245546311172349
   PubMed Web of Science ®Google Scholar
• SeeffLBMillerRNRabkinCSBuskell-BalesZStraley-EasonKDSmoakBL45-Year Follow-up of Hepatitis C Virus Infection in Healthy Young AdultsAnnals of Internal Medicine2000118132210511110644270
   PubMed Web of Science ®Google Scholar
• SeeffLBThe history of the “natural history” of hepatitis C (1968–2009)Liver International200929s1899919207971
   PubMed Web of Science ®Google Scholar
• SterlingRKStravitzRTLuketicVASanyalAJContosMJMillsASA comparison of the spectrum of chronic hepatitis C virus between Caucasians and African AmericansClinical Gastroenterology and Hepatology20042646947315181614
   PubMed Web of Science ®Google Scholar
• HutchinsonSJBirdSMGoldbergDJInfluence of Alcohol on the Progression of Hepatitis C Virus Infection: A Meta-analysisClinical Gastroenterology and Hepatology20053111150115916271348
   PubMed Web of Science ®Google Scholar
• WestinJLaggingLMSpakFAiresNSvenssonELindhMModerate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infectionJournal of Viral Hepatitis20029323524112010513
   PubMed Web of Science ®Google Scholar
• AdinolfiLEGMAndreanaATripodiMFUtiliRRuggieroGSteatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesityHepatology20013361358136411391523
   PubMed Web of Science ®Google Scholar
• BicaIMcGovernBDharRStoneDMcGowanKScheibRIncreasing Mortality Due to End†Stage Liver Disease in Patients with Human Immunodeficiency Virus InfectionClinical Infectious Diseases200132349242711170959
   PubMed Web of Science ®Google Scholar
• SulkowskiMSMSTorbensonMSHigginsYRapid fibrosis progression among HIV/hepatitis C virus-co-infected adultsAIDS200721162209221618090048
   PubMed Web of Science ®Google Scholar
• FattovichGGiustinaGDegosFTremoladaFDiodatiGAlmasioPMorbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patientsGastroenterology199711224634729024300
   PubMed Web of Science ®Google Scholar
• KimWRThe burden of hepatitis C in the United StatesHepatology2002365Bs30s412407574
   PubMed Web of Science ®Google Scholar
• FosterGRGoldinRDThomasHCChronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosisHepatology19982712092129425939
   PubMed Web of Science ®Google Scholar
• SIGN Managment of Hepatitis C http://www.sign.ac.uk/pdf/sign92.pdf2006
   Google Scholar
• NICEHepatitis C http://www.nice.org.uk/TA1062006
   Google Scholar
• EASL International Consensus Conference on Hepatitis C Paris, 1999 Feb 26–28: Consensus Statement*Journal of Hepatology199930595696110365827
   PubMedGoogle Scholar
• EdlinBRSealKHLorvickJKralAHCiccaroneDHMooreLDIs It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users?N Engl J Med2001719345321121411463019
   PubMed Web of Science ®Google Scholar
• ChangCHChenKYLaiMYChanKAMeta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis CAlimentary Pharmacology and Therapeutics20021691623163212197841
   PubMed Web of Science ®Google Scholar
• DieterichDTWassermanRBrauNHassaneinTIBiniEJBowersPJOnce-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfaAm J Gastroenterol200398112491249914638354
   PubMed Web of Science ®Google Scholar
• PockrosPJSMSchiffERSulkowskiMSProactive Study Group. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapyHepatology20044061450145815565613
   PubMed Web of Science ®Google Scholar
• MuirAJMJGrowth factors during HCV therapy may be “cost-effective”, but are they “effective”?Hepatology20064461400140317133467
   PubMed Web of Science ®Google Scholar
• McHutchisonJGGSSchiffERInterferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis CNew Eng J Med1998339148514929819446
   PubMed Web of Science ®Google Scholar
• PoynardTMPLeeSSRandomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusLancet1998352142614329807989
   PubMed Web of Science ®Google Scholar
• KjaegardLL KKGluudCInterferon alfa with or without ribavirin for chronic hepatitis C: Systematic review of randomised trialBMJ20013231151115511711405
   PubMed Web of Science ®Google Scholar
• LuxonBAGraceMBrassardDBordensRPegylated interferons for the treatment of chronic hepatitis C infectionClinical Therapeutics20022491363138312380630
   PubMed Web of Science ®Google Scholar
• FosterGRPegylated Interferons for the Treatment of Chronic Hepatitis C: Pharmacological and Clinical Differences between Peginterferon-[alpha]-2a and Peginterferon-[alpha]-2bDrugs70214716520108989
   PubMed Web of Science ®Google Scholar
• FriedMWShiffmanMLReddyKRSmithCMarinosGGoncalesFLJrPeginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionN Engl J Med20029263471397598212324553
   PubMed Web of Science ®Google Scholar
• MannsMPMcHutchisonJGGordonSCRustgiVKShiffmanMReindollarRPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet20013589286958965
   PubMed Web of Science ®Google Scholar
• DavisGMonitoring of viral levels during therapy of hepatitis CHepatology2002365Bs145s5112407588
   PubMed Web of Science ®Google Scholar
• HadziyannisSJSetteHMorganTRBalanVDiagoMMarcellinPPeginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine200432140534635514996676
   PubMed Web of Science ®Google Scholar
• TaylorLERichJDTashimaKTGholamPMTorrianiFJDieterichDTPeginterferon plus Ribavirin for Hepatitis C in HIV-Infected PatientsN Engl J Med20041125351222340234215564553
   PubMed Web of Science ®Google Scholar
• CarratFBani-SadrFPolSRosenthalELunel-FabianiFBenzekriAPegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients: A Randomized Controlled TrialJAMA20041215292232839284815598915
   PubMed Web of Science ®Google Scholar
• McHutchisonJGMannsMPatelKPoynardTLindsayKLTrepoCAdherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis CGastroenterology200212341061106912360468
   PubMed Web of Science ®Google Scholar
• McHutchisonJSulkowskiMScientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis CJournal of Viral Hepatitis200815747548118363672
   PubMed Web of Science ®Google Scholar
• AwadTTKHauserGStimacDMabroukMGluudCPeginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trialsHepatology5141176118420187106
   PubMed Web of Science ®Google Scholar
• PoynardTCacoubPRatziuVMyersRPDezaillesMHMercadierAFatigue in patients with chronic hepatitis CJournal of Viral Hepatitis20029429530312081607
   PubMed Web of Science ®Google Scholar
• WareJEJr BMMannocchiaMDavisGLInternational Hepatitis Interventional Therapy GHealth-related quality of life in chronic hepatitis C: Impact of disease and treatment responseHepatology199930255055510421667
   PubMed Web of Science ®Google Scholar
• YounossiZMGuyattGKiwiMBoparaiNKingDDevelopment of a disease specific questionnaire to measure health related quality of life in patients with chronic liver diseaseGut19998145229530010403745
   PubMed Web of Science ®Google Scholar
• YounossiZKJKincaidJThe effects of HCV infection and management on health-related quality of lifeHepatology200745380681617326207
   PubMed Web of Science ®Google Scholar
• BonkovskyHLWJGroup CIS. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapyHepatology19992912642709862876
   PubMed Web of Science ®Google Scholar
• CarithersRLJr SDBaylissMHealth assessment for chronic HCV infection: results of quality of lifeDig Dis Sci19961241Suppl 1275S80S PubMed PMID9011480
   PubMed Web of Science ®Google Scholar
• FortonDMTHMurphyCAAllsopJMFosterGRMainJWesnesKASDTR. Hepatitis C and cognitive impairment in a cohort of patients with mild liver diseaseHepatology200235243343911826420
   PubMed Web of Science ®Google Scholar
• NearyMPCSBaylissMSWareJEJrSustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patientsSemin Liver Dis199919Suppl 1778510349695
   PubMed Web of Science ®Google Scholar
• FontanaRJHussainKBSchwartzSMMoyerCASuGLLokASFEmotional distress in chronic hepatitis C patients not receiving antiviral therapyJournal of Hepatology200236340140711867185
   PubMed Web of Science ®Google Scholar
• NegroFAdverse effects of drugs in the treatment of viral hepatitisBest Practice and Research Clinical Gastroenterology242183192
   Web of Science ®Google Scholar
• BernfortLSennfÀltKReichardOCost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in SwedenScandinavian Journal of Infectious Diseases2006386–749750516798701
   PubMed Web of Science ®Google Scholar
• SiebertUSroczynskiGRossolSWasemJRavens-SiebererUKurthBMCost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis CGut2003352342543212584228
   PubMed Web of Science ®Google Scholar
• WongJBDavisGLPaukerSGCost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis CThe American Journal of Medicine2000108536637310759092
   PubMed Web of Science ®Google Scholar
• ButiMMedinaMCasadoMAWongJBFosbrookLEstebanRA cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis CAlimentary Pharmacology and Therapeutics200317568769412641518
   PubMed Web of Science ®Google Scholar
• ShepherdJBHCaveCBWaughNRPriceAGabbayJClinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluationInt J Technol Assess Health Care2005Winter211475415736514
   PubMed Web of Science ®Google Scholar
• SheerinIGGreenFTSellmanJDWhat is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?Drug and Alcohol Review200423326127215370005
   PubMed Web of Science ®Google Scholar
• GrishchenkoMGrieveRDSweetingMJde AngelisDThomsonBJRyderSDCost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practiceInternational Journal of Technology Assessment in Health Care2009250217118019331708
   PubMed Web of Science ®Google Scholar
• McCowanCKiddBFaheyTFactors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort studyBMJ2009616338jun16_4b222519535400
   PubMed Web of Science ®Google Scholar
• ZeuzemSPJLukasiewiczEDITTO-HCV Study GroupInternational, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis CJ Hepatol2005843225025716082736
   PubMed Web of Science ®Google Scholar
• DiagoMSMBronowickiJPZeuzemSRodriguez-TorresMPappasSCTietzANDIdentifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirinHepatology99999999 NA
   Google Scholar
• BermanKKwoPYBoceprevir an NS3 Protease Inhibitor of HCVClinics in Liver Disease200913342943919628159
   PubMed Web of Science ®Google Scholar
• McHutchisonJGEGGordonSCJacobsonIMPROVE1 Study Team. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionN Engl J Med2009108361151516
   Web of Science ®Google Scholar